Literature DB >> 10790856

Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons.

C V Borlongan1, T P Su, Y Wang.   

Abstract

A major problem in neural transplantation therapy is poor survival of grafted cells, which may be due to low cell viability prior to transplantation or scarce trophic factors available to the cells following transplantation. Recently, the delta enkephalin analogue [D-Ala(2),D-Leu(5)]-enkephalin (DADLE) has been demonstrated to protect against, as well as to reverse methamphetamine-induced loss of dopamine transporters. Here, we show that pretreatment with DADLE (0.0025, 0.005, 0.01 g/ml) dose-dependently enhanced cell viability of cultured primary rat fetal mesencephalic cells. In addition, DADLE administration in adult rats (4 mg/kg every 2 h, 4 injections, i.p.) prior to 6-hydroxydopamine lesions of the medial forebrain bundle, significantly reduced the severity of loss of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra 1 month post-lesion. This is the first report suggesting that DADLE can be used as a supplement factor for improving the cell viability of fetal mesencephalic cells and as a protective agent against neurotoxicity in a Parkinson's disease model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790856     DOI: 10.1097/00001756-200004070-00005

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  24 in total

1.  Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.

Authors:  Omar S Mabrouk; Riccardo Viaro; Mattia Volta; Ada Ledonne; Nicola Mercuri; Michele Morari
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

2.  Ischemic stroke may activate bone marrow mononuclear cells to enhance recovery after stroke.

Authors:  Bing Yang; Xiaopei Xi; Jaroslaw Aronowski; Sean I Savitz
Journal:  Stem Cells Dev       Date:  2012-08-03       Impact factor: 3.272

Review 3.  Treating childhood traumatic brain injury with autologous stem cell therapy.

Authors:  Shyam Dewan; Samantha Schimmel; Cesar V Borlongan
Journal:  Expert Opin Biol Ther       Date:  2018-02-15       Impact factor: 4.388

Review 4.  Delta Opioids: Neuroprotective Roles in Preclinical Studies.

Authors:  Shahid Husain
Journal:  J Ocul Pharmacol Ther       Date:  2018 Jan/Feb       Impact factor: 2.671

Review 5.  Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms.

Authors:  Connor Stonesifer; Sydney Corey; Shaila Ghanekar; Zachary Diamandis; Sandra A Acosta; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2017-07-23       Impact factor: 11.685

6.  Delta opioid peptide DADLE and naltrexone cause cell cycle arrest and differentiation in a CNS neural progenitor cell line.

Authors:  Shang-Yi Tsai; Chung-Ting Lee; Teruo Hayashi; William J Freed; Tsung-Ping Su
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

7.  Combination treatment of hypothermia and mesenchymal stromal cells amplifies neuroprotection in primary rat neurons exposed to hypoxic-ischemic-like injury in vitro: role of the opioid system.

Authors:  Yuji Kaneko; Naoki Tajiri; Tsung-Ping Su; Yun Wang; Cesar V Borlongan
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

8.  ADVANCES IN THE CELL-BASED TREATMENT OF NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY.

Authors:  Mibel M Pabon; Cesar V Borlongan
Journal:  Future Neurol       Date:  2013-03-01

9.  Hibernation-like state induced by an opioid peptide protects against experimental stroke.

Authors:  Cesar V Borlongan; Teruo Hayashi; Peter R Oeltgen; Tsung-Ping Su; Yun Wang
Journal:  BMC Biol       Date:  2009-06-17       Impact factor: 7.431

10.  Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats.

Authors:  Paul Olivier; Romain H Fontaine; Gauthier Loron; Juliette Van Steenwinckel; Valérie Biran; Véronique Massonneau; Angela Kaindl; Jeremie Dalous; Christiane Charriaut-Marlangue; Marie-Stéphane Aigrot; Julien Pansiot; Catherine Verney; Pierre Gressens; Olivier Baud
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.